ENDRA Life Sciences Issued Three New Patents

ENDRA Life Sciences Inc. has been granted three new patents—one in the United States and two in China. ENDRA’s intellectual property (IP) portfolio now includes 70 issued patents worldwide, enhancing the IP protection for its TAEUS system.

“Our IP portfolio has reached a new milestone of 70 issued patents globally. We believe this is a remarkable achievement for a company of our size and a testament to the innovation of ENDRA,” ENDRA Chairman/CEO Francois Michelon stated. “These newly issued patents protect and further differentiate ENDRA’s thermoacoustic systems in areas of high unmet clinical need, such as the early detection of steatotic liver disease.”
 
The three patents included:

• U.S. Patent No. 11806113, “Thermoacoustic Probe,” relates to a novel thermoacoustic probe with an optical transducer and an integrated wedge. This builds upon ENDRA’s U.S. Patent No. 11730374, which defines and protects ENDRA’s integrated wedge technology.
• Chinese Patent No. ZL 2021800299011 (the ‘011 patent), “Thermoacoustic Transducer with Integrated Switch,” relates to a novel system for reducing false signals in thermoacoustic imaging. ENDRA expects the ‘011 patent to be effective for all thermoacoustic imaging applications. The Chinese ‘011 patent is related to its parent patent, U.S. Patent No. 11172829.
• Chinese Patent No. ZL 2022800094336 (the ‘336 patent), “Acoustically Isolated Thermoacoustic Imaging Probe and Process of Manufacture,” protects ENDRA’s proprietary manufacturing process to acoustically isolate the radiofrequency element from the transducer element. The Chinese ‘336 patent is related to its parent patent, U.S. Patent No. US10996163. 

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), a technology being developed to visualize tissue like magnetic resonance imaging, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with more than 700,000 ultrasound systems in use globally today. TAEUS is initially focused on measuring liver fat as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects more than 2 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS, including tissue temperature visualization during energy-based surgical procedures.